All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, covering analyst for SMID-cap Biotech in the U.S. It is my pleasure to have the fireside chat with United Therapeutics. We have the CFO, James Edgemond, and we also have Investor Relations, Harry Silvers. Welcome, gentlemen.
Great, Roger. Thanks for having us. I'm going to turn it over to Harry real quick to do a forward-looking statement.
Sorry, just to check the box here. Today we may make some forward-looking statements, so for any risks and uncertainties associated with those statements, please refer to our latest filings on Forms 10-K and 10-Q. Now back to James.
Great. Again, Roger, thanks for having Harry and I. We actually have Dr. Betsy Eades here, who does corporate development for United Therapeutics, with us today. Again, appreciate you hosting United Therapeutics. Overall, Roger, just a couple words just to start. Overall, we're very proud of what United Therapeutics and all the Unitherians have been doing during and across the third quarter that we recently reported. From a commercial standpoint, it's fair to say that the commercial strategy and the base business is working very well. We reported the highest revenue ever total for the organization at $833 million, and within that, TYVASO reported its highest revenue ever of $504 million. Again, the base business we think is working well. The commercial strategy is working well.
On the development side, during the quarter and the updates, it is going to be a very busy 2027. The FDA did accept the sNDA to use nebulized TYVASO in idiopathic pulmonary fibrosis that has a PDUFA date of April 26th. The FDA accepted the NDA for ralinepag for use in PAH as the only once-a-day oral prostacyclin that has a PDUFA date in June 24th. We fully enrolled and we are going to unblind in the second half of 2027, the TETON clinical study for progressive pulmonary fibrosis, so PPF, that has a very large patient population, and we will unblind that in the second half of 2027. In addition to the myriad and numerous research projects that Martine has going on within the organization to continue to provide the best patient care possible. Thanks for the opening and giving us a chance to have a word.
Absolutely. All right. Maybe we focus on the base commercial business for a moment, TYVASO, and then particularly for PH-ILD. You recently have a very big win on the patent side, and then you can now have exclusive kind of rights for the PH-ILD side. Your core Q3 is pretty clean, right? Record referral in October as well. How should we think about Q4 and then into 2027, particularly the split between the PH-ILD versus PH? How much growth are we going to see in the PH-ILD side?
Yeah. Thank you, Roger. On the PH-ILD side, which is a main growth driver, and it will be for us as we look forward going forward. In general, if you were to go back to Q2, what Michael Benkowitz talked about coming out of the quarter was strength in the starts and the referrals. You saw that across Q3 in terms of really patient demand that drove this revenue growth. Michael also mentioned in the earnings call in October, we had the highest number of referrals across our commercial portfolio of over 1,000 referrals in the month of October, which is the highest record ever for us in referral basis. I think that goes to further demonstrate the base business and the commercial strategy is working well.
One aspect of your question is during this calendar year, Michael hired additional sales teams that will eventually transition to support the IPF launch. Those sales teams were in the field further educating physicians, talking about more on the PH-ILD side. We are not commercially promoting on the IPF side yet. You are seeing those relationships develop, and where I think you are going to see the benefit of those additional sales teams is in Q4 and across 2027. I think they will be in chair, and they will really start to have an impact. The Q3 was really momentum coming out of Q2 that demonstrated Q3 with a strong revenue performance.
How should we think about the lead time from the referral to the revenue booking? And then also, TYVASO PH-ILD continued to grow, and this growth trajectory well accelerate with the reason no patent providingâ into 2027. How should we say about that?
Yeah. Thanks, Roger. With the settlement going forward, there's various things that will be done in terms of communicating to physicians regarding the transition of patients that were on another therapy to another form. So from a Liquidia product to TYVASO DPI or another therapy in the TYVASO DPI space. There's certain things there that are happening, and there will be a label amendment, which I think will give us kind of unfettered access to these PH-ILD patients on a going-forward basis. Naive patients coming in or being diagnosed with PH-ILD would transition, we believe, on the TYVASO DPI going forward as an effective therapy. I think you would start to see that momentum in Q4 and going into 2027 for the naive patients that are new to therapy.
Mm-hmm. Okay. How about the switcher? I believe you said, in the beginning, at least in the near term, the modest switching.
As they amend the label without the PH-ILD anymore, they cannot promote from day one, and the payer may react to the new label. So how should we think about the future switching kind of dynamic?
Yeah, correct. When Liquidia would update their label to remove the PH-ILD indication from their label, and you think about TYVASO DPI, that would be an effective therapy for these newly diagnosed patients to go straight on.
Yeah.
Again, then from a payer perspective, once the label is updated, that would make its way through the payer platforms in terms of a reimbursement perspective. Without it being on label the reimbursement would change for them. There's various things that happen under the settlement agreement, from communications from Liquidia to the prescribing physicians, to the updating of the label, and then further the attestation on the newly diagnosed patients to go on to YUTREPIA. The physician has to actually assert that their indication is for PAH only.
Again, any patients that would be diagnosed with PH-ILD would be patients that were able to go on TYVASO DPI on a going-forward basis.
Yeah.
It will take time, for example, for the label to be amended on a going-forward basis. But once the label is amended, of course, going forward, TYVASO DPI would be a very good therapy for these patients to go on.
Yeah. So, I understand this is not your process controlled by you, but if they say, sometime next year, they amend the label, how fast do you think the payer will react to update the coverage and then the reimbursement policy?
Yeah, it's hard for us to say because the payers have their own internal processes, Roger. So it's hard for me to say that after such and such a time period. I think what's important is to get the label updated.
To get that communicated back to the payers. But at this point, it would be hard for me to say this timeline for a new payer.
Yeah.
Hoping it's done by the beginning of the year with the reauthorization process that typically happens. But again, I'm not in a position to say.
Yeah. But is that like a set time for a payer to make some amendment, or that they can do ad hoc if they have some additionalâ
Yeah, I'm sure it'sâ
I don't know if they have the mechanism.
No, it's really going to vary payer by payer, and we're just not in a position to comment on that.
Okay, got it. In terms of the gross-to-net, right, I think that part, will this settlement help you to sustain the gross-to-net a bit better, given you have basically less competition on the PH-ILD side?
Yeah, Roger, we don't get into forecasting kind of that gross-to-net on the rebate side.
It's certainly something that we have done historically, and I think we'll need to let kind of that process play out. Before we would commit to saying we would have an impact on the rebating side. I think more to come there. I think it is safe to say right now we feel very comfortable on where the rebating is in the moment, but more to come on a prospective basis.
Got it. All right, last question about the base business is, I know I grill you a little bit more. But I think just without revealing the real exact of the methods, how you are going to monitor the off-label use of the PH-ILD on the competitive side. How confident you are this will be exclusively to the TYVASO from here for the indication?
Yeah. Thanks, Roger. We feel under this settlement agreement that the guardrails and things that are put in placeâ should be abided by in terms of communication, in terms of label update, on a going-forward basis. And we will clearly be monitoring that on a going-forward basis through various means. And if they are not abided by, then we are certainly going to take action to, again, protect the intellectual property and what we believe is the right and updated label. There are means and methods going forward that we will pay really close attention to make sure this legal settlement is abided by.
So far, concerns, any risk you have seen, or so far it is pretty abided?
It is pretty early, but again, I think what is important is just under the terms of the settlement, we are going to continue to monitor this extremely closely and protect what we believe was the right decision in the court settlement.
Okay. Let us move on from the base. I think you have a lot of the growth going to come in. Then particularly for the two IPF, TYVASO and then the ralinepag. For IPF, we were all impressed by the TETON-1 and 2 data. How should we think about the label language? Any special kind of features you will highlight? Two is, what will be the initial wave of the patient from the IPF side? Because we have a generic, we also have a background and an oral antifibrotic drugs, but TYVASO can be used on top of that, and it can also be used as a monotherapy.
Yeah, thanks. We're kind of a ways away, I would say, from real detailed labeling discussions. I think the success of the trial and the clinical results were extremely impressive.
I think there would be broad use of nebulized TYVASO in the IPF setting.
In the clinical trial, background therapy we've seen was used in the trial. I know it can be used on top of background therapy in terms of the results. I think as we get closer, we can probably give a better idea with respect to real details on the labeling, but I think it should be broadly used overall.
Do you want to fill in on the patient side or?
Sure. Just kind of on top of what he just said, the results were really highly generalizable when you think about what we saw on top of background therapy across all subgroups. So, where it lands in the prescribing regimen, as you asked, it really could be adjunctive, refractory, potentially even first line. Again, very highly generalizable results. It is going to ultimately be determined by physician medical judgment and the patient needs.
Got it. All right. Assuming you will get approval, which is highly likely you will get that, how far along have the payer and the reimbursement discussion been going on? What is the feedback on the pricing given TYVASO is about a bit higher than the current oral drugs?
Yeah. On the pricing point, Roger, nebulized TYVASO is approved currently. At this point, we do not anticipate any changes of the price, once your reference of other therapies in the market have a different price point. At this point, I do not think we anticipate changing the price for nebulized TYVASO at this point going forward.
Yeah. Any initial feedback you got from the payer given the different pricing?
Yeah. Not yet in terms of payer feedback to get into the conversations around. There is obviously things like the local coverage determination that we will need to do on a going forward basis for those folks that are in Medicare.
Yeah.
But there are also commercial patients, there will be patients in Medicare Advantage that will not necessarily be subject to the local coverage determinations. So I think we will know more as we get closer, but of course, the process for LCD determination will be needed since it is a nebulized Part B therapy for reimbursement.
That is right. As you launch the IPF, how quickly you think the broader, getting towards the similar level of the broader coverage as PH-ILD for the IPF for TYVASO?
In terms of payer?
Yeah, payer. Yeah.
I think it's a process that we'll work through. I think what Michael Benkowitz and his teams are doing right now are having those conversations and getting ready, but I think more to come as we get into 2027 and closer to that PDUFA date.
Got it. You still have not really put too much commercial effort ex-U.S. just by yourself, and then how you think about the IPF given this is a pretty big indication?
Yeah, I think Harry's going to take on this.
Sure. A recent update from our end, our partner in Europe, Ferrer, they recently filed for EMA in the European regions upon which they can operate per our agreement. That is certainly one step that we've taken towards bringing it forward, that is nebulized TYVASO and IPF in this part of the world.
Yeah. Okay. Europe. All right. On the ralinepag, so recently you say your supplier has some OAI. So how quickly this can be resolved and how confident this PDUFA date will be intact?
Thank you. We did disclose in the last 10-Q the API manufacturer with ralinepag is responding to the FDA's inquiries on some findings. That is top priority for us internally, and obviously the quickest path is to support the manufacturer remedy those findings with the FDA. But we're also pursuing opportunities to think about an additional manufacturer should we need to bring up during that timeframe. But overall, it's a top priority that we disclosed, and we're working pretty hard internally to get through that. Maybe a long-term strategy, and it certainly wouldn't be done in time, is to bring some of that manufacturing in-house, like we do with our current treprostinil API environment.
Yeah. Another thing, you just buy down the royalty from Pfizer.
Yeah.
That speaks to the confidence. You think this is definitely going to get approval and then go launch to a very high level.
We do. On the royalty buy-down, we felt it was a great opportunity, and candidly, Betsy had some great negotiations to get to that point. We felt based upon the conviction in ralinepag, what a game-changing molecule this could be for the organization, we felt it was the right time to eliminate all future royalties, both on the oral side as well as any inhaled products that are developed in the future. Through Betsy's negotiations, it was a great opportunity for us to deploy some capital. I think broadly speaking, it does go to the confidence that we have in ralinepag and what the ability of currently at the FDA with the NDA, a once-a-day oral, very potent prostacyclin. We feel very confident in. I think there is a disconnect between what some of the sell side and Wall Street think versus what the prescribing community think.
Yeah
That we think will solve itself in time. But the physicians in the clinical trial were very enthusiastic and thought there was an opportunity for every PH patient right behind frontline therapy to be prescribed ralinepag. We have a lot of confidence and conviction, and we will bring Wall Street along with us in the sell-side community.
Okay. Myself included. So, definitely I am not quite at the highest revenue opportunity compared to the IPF. Okay. We should talk about all the other pipeline a little bit earlier. Some of them already also late stage.
Sure.
For the Tresmi, that delay, what exact FDA ask for additional data, and then how is that including some of the data from patient, or what is the nature of the data they are requesting and how fast you think you can generate those data?
Yeah, sure. It is nothing new. You said, outcomes patient data. That is not the case here. We just need more data on the PK and CMC side on top of what we have already done in the PK and CMC side. Unfortunately, we need time to produce that, so we are not going to make the originally communicated date end of this year, and that is why it is slipping into 2027.
Okay. You did say it is 2027, you said slipping to 2027. Should we think about this early part of 2027 or maybe later part of 2027? Any granularity will be helpful for us to model that.
We will provide more information when we have it.
Okay, that is fine. For the PPF, that is actually the phase III, right?
Right
With the TETON-1 and 2, is your level of confidence get higher, lower, or I think probably higher or stay the same? Also on the physician side, now you have a positive IPF. Are they start to think about more potential use for the PPF if the TETON PPF is positive?
Sure. In terms of confidence, that is unwavered. We have always been highly confident even before we knew the results of the TETON IPF study, and the results of the TETON IPF study make us even more confident in PPF. The underlying fibrosis and progression of the disease are relatively similar across IPF and PPF, not to mention it works with other drugs in both diseases, so we are confident that we will see the exact same. What was your second question regardingâ
Because physician treating IPF patient, they also probably are treating the PPF patient.
That's right.
So with the data from IPF or the TETON-1 and 2, if the PPF, TETON-PPF data is positive, will they start to think about more prescribing habit?
Not sure how that works out from a reimbursement perspective. But certainly, if doctors think that their patients can benefit from it and they want to write the prescriptions, they'll do so. Just not sure how that translates to revenue recognition right now.
Yeah. Okay. Yeah. Okay, good. So another major indication you've been starting to talk more is the PH-COPD. How should we think about this phase II, and given you have some history in the same indication, how should we think about the confidence level now, and what's the learning you apply to this new phase II, and can increase the likelihood of success?
Yeah, so what you are referring to is the SUMMIT clinical trialâ
SUMMIT, yeah.
âwhich is PH-COPD. And reference, there was a prior clinical trial called PERFECTâ
PERFECT. Mm-hmm.
âthat was done around, actually was open around the time of COVID. There was a decision to stop that trial for a variety of reasons. I think what changed today is we are now going to use an SMI device
in this trial. I think the clinical team has a lot more experience in this area in terms of running this trial for a very large indication. From a confidence perspective, I think we have been able to learn from the learnings of PERFECT, and also just the learnings of these additional clinical trials for IPF and PPF. This should be an opportunity for this clinical team to do what is now a phase II study, so it is only 40 patients.
But to run that trial and then think about the next phase III trial. I think it is using a new device, and I think it is a very talented and experienced clinical team in a disease state that needs some therapy.
Any patient population inclusion, exclusion criteria you learned from the PERFECT and then can apply to this SUMMIT?
Yeah, not yet in terms of. Well, there are learnings, but in terms of disclosing, I think we'll be able to do that more when we disclose the protocol.
Yeah, that's fair. Then the triple pill, triple mechanism pill in one pill, that's something pretty interesting, but it seems the FDA gave you some feedback, and then you probably will take a little bit longer to get there in terms of the filing, I need.
Sure. The program is actually on pause now.
Really just based on the feedback that we got from the FDA that a full factorial study design would be required for approval. Just based on how patients in PH typically are treated today, it would be pretty difficult to enroll such a study where patients have to be restricted on some therapies versus others. So again, the program's on pause as we work out an additional development pathway.
Yeah. Because it's a triple combo. They're not treating this as the one drug. They're actually treating the combination drug.
Correct.
Okay. Got it. All right. The ralinepag DPI, that's also another major one, once-a-day probably, and also you have the competitive landscape, moving towards the once-a-day DPI. How should we think about that in terms of the potency, the efficacy, indication, and the timeline-wise in terms of the development timeline?
Yeah, absolutely. We'll learn a lot of this as we move through the development pathway. The expectation is to have an IND here pretty soon and kick off a phase I right behind that.
What we know from the ADVANCE OUTCOMES study is that ralinepag is dose QD, and that it's a highly potent version of treprostinil. We're really optimistic that in the areas of treprostinil where we know the drug works, we could potentially see even greater efficacy. That's to be determined as we move along the clinical development path.
Okay. Got it. Xeno. This is going to be transformative. You are accumulating patient and then also data coming. When and how are we going to see the data, and then what will be the next step in terms of that licensure?
Yeah. Thanks, Roger. It's a good question. As we talked before, we're going to finish the six transplants. We're still on track by the end of 2026, for the EXPAND clinical trial, which is your 10 gene edit UKidney.
12 weeks after that, we will accumulate the data and then meet with the FDA to share that data, which was what was determined before on those initial six patients. Based upon that review, then the FDA will give us, we hope, the green light to proceed and complete the rest of the transplants under that program. Currently, it was scheduled, or when we started at a max of 50 patients. That trial could be resized, but this is a phaseless, BLA-enabling clinical trial. In terms of the data, I wouldn't expect to see a lot of patient data when we go to the FDA, but I think it would be something later on once the trial is done and you can do a full poster or some presentation, or other medical journals in terms of writing about the clinical trial.
Again, year-end to finish the transplants, wait 12 weeks, go to the FDA, share the data, and then get the green light, we hope, to proceed with the trial with the remaining transplants.
Excellent. All right. Last minute, in terms of, you have a new product launching, you do have your commercial business generating revenue, and then also you have an earlier pipeline. How should we think about the G&A and R&D moving forward, particularly some high-level guidance? We are not asking forâ
Yeah
âthe formal guidance.
Yep. Thanks, Roger. The high-level guidance is we apply an algorithm where we do not spend a percentage of prior year revenues, and historically it has been 50% in terms of cash operating budgets. It does not include things like the legal budget and things that you do not want to put a cap on, as illustrated by the success we recently had in the settlement. But going forward in 2027, we are going to increase that budget algorithm to be no greater than 55% of prior year revenues for cash operating budgets. We are going to continue to try to be good financial stewards and make really smart decisions about how we allocate those budget dollars internally for the highest and best return overall.
Excellent. All right. Thank you.
Thank you.
Yeah. Thank you, James. Thank you, Harry. Thank you, everyone.